Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Panagiotis Zikos

Effectiveness of 5-Azacytidine in Older Patients With High-Risk Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia: A Retrospective Analysis of the Hellenic (Greek) MDS Study Group

Journal of Geriatric Oncology

English

The Prognostic Significance of Chromosome 17 Abnormalities in Patients With Myelodysplastic Syndrome Treated With 5‐azacytidine: Results From the Hellenic 5‐azacytidine Registry

English

Related publications

CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Clinical Lymphoma, Myeloma and Leukemia

English

Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

English

A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma

English

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

Journal of Clinical Oncology

English

Role of BCL2L10 Methylation and TET2 Mutations in Higher Risk Myelodysplastic Syndromes Treated With 5-Azacytidine

English

Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities

English

Expanded Safety Analysis of Pevonedistat, a First-In-Class NEDD8-activating Enzyme Inhibitor, in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

English

FLAMSA-RIC for Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine

2019

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Panagiotis Zikos

Effectiveness of 5-Azacytidine in Older Patients With High-Risk Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia: A Retrospective Analysis of the Hellenic (Greek) MDS Study Group

The Prognostic Significance of Chromosome 17 Abnormalities in Patients With Myelodysplastic Syndrome Treated With 5‐azacytidine: Results From the Hellenic 5‐azacytidine Registry

Related publications

CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

Role of BCL2L10 Methylation and TET2 Mutations in Higher Risk Myelodysplastic Syndromes Treated With 5-Azacytidine

Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities

Expanded Safety Analysis of Pevonedistat, a First-In-Class NEDD8-activating Enzyme Inhibitor, in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

FLAMSA-RIC for Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis